Glycosylated Recombinant Human Interleukin-7
Renal Pelvis Urothelial Carcinoma
Explore 17 assets in Renal Pelvis Urothelial Carcinoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03513952CT.gov Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Pelvis Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Glycosylated Recombinant Human Interleukin-7 (this asset) | National Cancer Institute (NCI) | P2 | CCC · 52 |
| Nivolumab | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Pembrolizumab | Fred Hutchinson Cancer Center | P3 | BB |
| Muamycin | UroGen Pharma Ltd. | P3 | B |
| Relatlimab | National Cancer Institute (NCI) | P2/3 | B |
| Atezolizumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | B |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | B |
+12 more in the Renal Pelvis Urothelial Carcinoma cohort
Other indications for Glycosylated Recombinant Human Interleukin-7
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypogonadism | — | P2 | CCC · 52 |
| Metastatic Prostate Carcinoma | — | P2 | CCC · 52 |
| Prostate Cancer | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Glycosylated Recombinant Human Interleukin-7 in Renal Pelvis Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/glycosylated-recombinant-human-interleukin-7-renal-pelvis-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →